South African Health Minister Zweli Mkhize has confirmed that the sale of one million doses of the AstraZeneca coronavirus vaccine received from the Serum Institute of India last month has been concluded.
The vaccines were sold to 14 African countries after South Africa suspended its planned usage to vaccinate healthcare workers when it was found to have limited efficacy against a new variant of the virus that became dominant in the country during a second wave of the pandemic towards the end of last year.
Instead, South Africa opted to use alternative vaccines to provide some level of immunity to thousands of healthcare workers, but concerns have been expressed over the slow rate of a planned three-phase vaccination programme amid delays in the delivery of vaccines.
"In the past weeks, the department has had to ensure that all member states identified by the African Union (AU) vaccine acquisition team as recipients of the vaccines are compliant and have obtained all regulatory approvals, permits and licenses to roll out the vaccines in their respective countries," Mkhize said in a statement released on Sunday.
Mkhize confirmed that the full purchase amount was received by the Department of Health on Monday last week. However, he did not disclose the amount.
"The AU and South African teams then ensured that all logistical arrangements are in place for the shipment of vaccines," the minister said.
The AU had found that the benefits of using the AstraZeneca vaccine, which has been suspended in a number of countries over safety fears, far outweighed the risks. The suspension came after reports of the vaccine causing blood clots in a few cases.
The first batch of vaccines was shipped to nine member states of the AU on Sunday, while the remaining will be collected by five other countries later this week.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU